Altena Mariette R, Kleefstra Nanne, Logtenberg Susan J, Groenier Klaas H, Houweling Sebastiaan T, Bilo Henk J
Diabetes Centre, Isala Clinics, Zwolle, The Netherlands.
Blood Press. 2009;18(5):273-9. doi: 10.3109/08037050903272925.
Hypertension is a chronic disorder with a high prevalence worldwide. Despite considerable efforts, it is sometimes hard to reach treatment goals for blood pressure (BP) with classical treatment options. Reducing breathing frequency has been advocated as a method to reduce BP.
A randomized, single-blind, controlled trial was conducted in 30 non-diabetic patients with hypertension over a period of 9 weeks to evaluate the effect of a device that helps to slow breathing (Resperate) on BP and quality of life (QoL). The control group listened to music and used no other therapeutic device.
There was no significant difference in change in BP between intervention and control; BP -4.2 mmHg (95% CI -12.4 to 3.9)/-2.6 mmHg (95% CI -8.4 to 3.3). This result did not alter in post hoc analyses, when patients not achieving target breathing frequency (<10 breaths/min) or non-compliant patients were excluded. QoL did not change over time.
We found no effect of the Resperate on BP or QoL compared with the control group. We conclude that, at this moment, this device has no added value in the treatment of hypertension.
高血压是一种在全球范围内患病率很高的慢性疾病。尽管付出了巨大努力，但有时采用传统治疗方案很难达到血压（BP）治疗目标。降低呼吸频率已被倡导作为一种降低血压的方法。
对30名非糖尿病高血压患者进行了一项为期9周的随机、单盲、对照试验，以评估一种有助于减缓呼吸的设备（Resperate）对血压和生活质量（QoL）的影响。对照组听音乐且不使用其他治疗设备。
干预组和对照组之间血压变化无显著差异；血压为-4.2 mmHg（95%可信区间-12.4至3.9）/-2.6 mmHg（95%可信区间-8.4至3.3）。当排除未达到目标呼吸频率（<10次/分钟）的患者或不依从患者后，该结果在事后分析中未改变。生活质量随时间未发生变化。
与对照组相比，我们发现Resperate对血压或生活质量无影响。我们得出结论，目前，该设备在高血压治疗中没有附加价值。
